Advertisement
![Picture [iito] Life Science Business Portals Media Data 2022 2 650x100px](/banner/iito-business-intelligence-20220401-650-100-promote-brand-to-decision-makers.jpg)
Document › Details
BlueRock Therapeutics LP. (1/21/20). "Press Release: Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes". Leiden & Cambridge, MA.
![]() |
Organisation | BlueRock Therapeutics LP |
Group | Bayer (Group) | |
Organisation 2 | Ncardia Services B.V. | |
Group | Kiniciti Bio (WCAS invesment platform) (Group) | |
![]() |
Product | iPSC technology (induced pluripotent stem cell technology) |
Product 2 | contract manufacturing (biologicals) | |
![]() |
Person | Braam, Stefan (Ncardia 201709– CEO before Pluriomics) |
Person 2 | Nuwaysir, Emile (Bayer 201904 CEO of BlueRock Therapeutics) | |
Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.
“BlueRock is a leader in the field of cell therapy and our collaboration is a perfect match of mission and capabilities. This relationship allows us to utilize our experience in iPSC process development to help advance potential cell therapies for cardiac diseases,” said Stefan Braam, CEO of Ncardia.
“There are hundreds of millions of people worldwide that suffer from degenerative cardiovascular disease where the root cause is the loss of healthy heart muscle cells, and where medical treatment options are limited. BlueRock’s authentic cellular therapy is a novel approach that has the potential to transform the lives of patients, but will require the manufacture of our cell therapies at unprecedented scale. The Ncardia team has developed key technologies related to this scale-up challenge, and we are pleased to work with them as we advance BlueRock’s novel CELL+GENE platform towards the clinic and those patients in need”, said Emile Nuwaysir, President and CEO, BlueRock Therapeutics.
About BlueRock Therapeutics
BlueRock Therapeutics, a wholly owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock’s culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com.
About Ncardia
Ncardia believes that stem cell technology can deliver better therapies to patients faster. We bring cell manufacturing and process development expertise to cell therapy by designing and delivering human induced pluripotent stem cell (iPSC) solutions to specification. Our offerings extend from concept development to pre-clinical studies, including custom manufacturing of a range of cell types, as well as discovery services such as disease modelling, screening, and safety assays. For more information, visit www.ncardia.com.
Contact
BlueRock: media@bluerocktx.com
Ncardia: media@ncardia.com
Record changed: 2022-05-02 |
Advertisement
![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg)
More documents for Bayer (Group)
- [1] Bayer AG. (6/9/22). "Press Release: Bayer’s Vividion Emerging as Significant Player in San Diego Biotech Hub". Leverkusen & San Diego, CA....
- [2] Bayer AG. (6/8/22). "Press Release: Bayer’s BlueRock Therapeutics Establishes European Site for Cell Therapy Innovation". Berlin....
- [3] Bayer AG. (5/31/22). "Press Release: BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson’s Disease". Cambridge, MA....
- [4] Atara Biotherapeutics, Inc.. (5/19/22). "Press Release: Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer". South San Francisco, CA....
- [5] Bayer AG. (4/22/22). "Press Release: Bayer to Create Ag Biologicals Powerhouse Partnership with Ginkgo Bioworks, Advancing Joyn Bio Technology Platforms". Monheim....
- [6] Bayer AG. (4/2122). "Press Release: Bayer Appoints Tara Frenkl as the New Head of Oncology Development at Its Oncology Strategic Business Unit". Berlin....
- [7] Bayer AG. (4/13/22). "Press Release: Bayer Receives Approval for Precision Oncology Treatment Vitrakvi in China [Not intended for U.S. and UK Media]". Berlin....
- [8] Bayer AG. (4/1/22). "Press Release: Breakthrough Innovation Forum. Bayer Set to Drive Breakthrough Innovations in the Life Sciences". Leverkusen....
- [9] Bayer AG. (3/31/22). "Press Release: Bayer to Strengthen Global Pharmaceuticals Production Network. Planned Investments of around €2bn over Next Three Years [Not intended for U.S. and UK Media]". Berlin....
- [10] Bayer AG. (3/22/22). "Press Release: Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations". Tel Aviv....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top